HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Attend Upcoming Investor Conferences

Chi-Med to Attend Upcoming Investor Conferences

LONDON, May 08, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

The discussion will be webcast live and can be accessed at in the Shareholder Information section under “Events, Circulars & Forms.”  Investors interested in listening to the live webcast should log on before the start time to download any software required.  A replay of the event will be available shortly thereafter for approximately 90 days.

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

  • Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

     
  • Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

     
  • Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President+852 2121 8200
Annie Cheng, Vice President+1 (973) 567 3786
  
Media Enquiries 
Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile) 

Europe – Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Asia – Joseph Chi Lo / Zhou Yi, Brunswick+852 9850 5033 (Mobile), / +852 9783 6894 (Mobile),
  
Nominated Advisor 
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited+44 (20) 7886 2500

EN
08/05/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): The Promising ATTC Platform And Late-Stage P...

Combined with a robust pipeline and partnership strategy, HUTCHMED expects its ATTC platform to deliver potentially transformative cancer and immunology treatments to patients around the world. The company has also seen smooth R&D progress in its various late-stage programmes, eg Fruquintinib (FRUSICA-2 study), Savolitinib registration studies, Surufatinib for pancreatic cancer, Sovleplenib for ITP and wAIHA, and Fanregratinib in IHCC. HUTCHMED will likely embrace a new wave of new indication/pr...

Carol Dou Xiao Qin ... (+3)
  • Carol Dou Xiao Qin
  • Greater China Research Team
  • Sunny Chen

Greater China Daily: Tuesday, November 4, 2025

Top Stories Strategy | Alpha Picks: November Conviction Calls HSI and MSCI China fell 3.5%/4.0% mom in October, dragged by renewed US-China trade tensions and lack of fresh policy signals from the 4th Plenum. We remain constructive in the medium term but expect further consolidation as uncertainties persist. The best performer among our picks was SELL-rated Li Auto (+21.4% mom). For November, we rotate into oversold names with near-term upside: add AIA, LINK REIT, NAURA, Pinduoduo, PICC P&C and...

 PRESS RELEASE

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Even...

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event — HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy and safety — — Progress in global and China trials, including FRUSICA-2, SANOVO, surufatinib’s PDAC and fanregratinib’s IHCC studies, advances HUTCHMED’s late-stage pipeline — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHM...

 PRESS RELEASE

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC Int...

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics — First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload — — Preclinical data shows robust antitumor activity with synergistic and bystander killing effects — HONG KONG and SHANGHAI ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare Bi-Weekly: Seeing A Temporary Setback But Fundamental...

Investors took profits on the sector amid concerns over possibly worsening US-China geopolitical tensions. Following the largest share price gain in previous months, biotech and CRDMOs saw significant setbacks in the first two weeks of October. We believe the pullback is temporary as the trend of innovation and globalisation among Chinese biopharmas remains strong, driven by robust pipelines, growing product launches and earnings expansion. CRDMOs and internet healthcare companies also expect to...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch